Clinical Trials Browser

Melanoma × epacadostat × 90 days × Clear all

NCT01604889 2026-04-21

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Phase 1/2 Terminated

Melanoma, Neoplasms, Skin Neoplasms